Liang Winnie S, Beaulieu-Jones Brett, Smalley Susan, Snyder Michael, Goetz Laura H, Schork Nicholas J
Net/Bio Inc, Los Angeles, CA, United States.
Translational Genomics Research Institute (TGen), Phoenix, AZ, United States.
Front Pharmacol. 2024 Mar 13;15:1348112. doi: 10.3389/fphar.2024.1348112. eCollection 2024.
In recent years, the development of sensor and wearable technologies have led to their increased adoption in clinical and health monitoring settings. One area that is in early, but promising, stages of development is the use of biosensors for therapeutic drug monitoring (TDM). Traditionally, TDM could only be performed in certified laboratories and was used in specific scenarios to optimize drug dosage based on measurement of plasma/blood drug concentrations. Although TDM has been typically pursued in settings involving medications that are challenging to manage, the basic approach is useful for characterizing drug activity. TDM is based on the idea that there is likely a clear relationship between plasma/blood drug concentration (or concentration in other matrices) and clinical efficacy. However, these relationships may vary across individuals and may be affected by genetic factors, comorbidities, lifestyle, and diet. TDM technologies will be valuable for enabling precision medicine strategies to determine the clinical efficacy of drugs in individuals, as well as optimizing personalized dosing, especially since therapeutic windows may vary inter-individually. In this mini-review, we discuss emerging TDM technologies and their applications, and factors that influence TDM including drug interactions, polypharmacy, and supplement use. We also discuss how using TDM within single subject (N-of-1) and aggregated N-of-1 clinical trial designs provides opportunities to better capture drug response and activity at the individual level. Individualized TDM solutions have the potential to help optimize treatment selection and dosing regimens so that the right drug and right dose may be matched to the right person and in the right context.
近年来,传感器和可穿戴技术的发展使其在临床和健康监测环境中的应用日益广泛。生物传感器用于治疗药物监测(TDM)是一个尚处于早期但前景广阔的发展领域。传统上,TDM只能在经过认证的实验室进行,且用于特定场景,即根据血浆/血液药物浓度的测量来优化药物剂量。尽管TDM通常用于涉及难以管理的药物的情况,但基本方法对于表征药物活性很有用。TDM基于这样一种理念,即血浆/血液药物浓度(或其他基质中的浓度)与临床疗效之间可能存在明确的关系。然而,这些关系可能因个体而异,并且可能受到遗传因素、合并症、生活方式和饮食的影响。TDM技术对于实现精准医疗策略以确定个体药物的临床疗效以及优化个性化给药将具有重要价值,特别是因为治疗窗可能因人而异。在本综述中,我们讨论了新兴的TDM技术及其应用,以及影响TDM的因素,包括药物相互作用、多种药物并用和补充剂的使用。我们还讨论了如何在单受试者(N-of-1)和汇总的N-of-1临床试验设计中使用TDM,从而有机会在个体水平上更好地捕捉药物反应和活性。个性化的TDM解决方案有可能有助于优化治疗选择和给药方案,以便使正确的药物和正确的剂量与合适的人在合适的情况下相匹配。